港股異動丨君實生物大漲11.55% 科創板上市將為公司帶來資金上的支撐
格隆匯4月27日丨君實生物(01877.HK)大漲11.55%,報38.15港元,總市值299億港元。君實生物上週公佈,3月30日,上交所發佈了《科創板上市委2020年第7次審議會議結果公告》,公司首次公開發行股票並在科創板上市的申請已通過上市委審議。目前,公司首次公開發行股票並在科創板上市申請的審核狀態為“提交註冊”。君實生物目前有20項在研產品,其中9項處於臨牀階段。在研發投入不斷擴大的情況下,“H+A”上市模式對尚未盈利的生物醫藥股可以帶來資金上的支撐。行業層面,生物安全法草案二審稿26日提請十三屆全國人大常委會第十七次會議審議。2019年10月,十三屆全國人大常委會第十四次會議對生物安全法草案進行了初次審議。經廣泛徵求意見修改形成的二審稿共計十章八十五條,聚焦防範和應對生物威脅,保障人民生命健康,促進生物技術健康發展,保護生物資源和生態環境。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.